This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GTXI SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter LLP Announces Investigation Of GTX Inc.

The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of GTX Inc. (GTX) (NASDAQ: GTXI).

On August 19, 2013, GTX announced that enobosarm, its potential treatment for muscle wasting in lung cancer patients, fell short of key goals agreed upon with the Food and Drug Administration in two phase III clinical trials in terms of increasing lean body mass and improving physical function.

Upon the above news, GTX shares have declined over 60% in trading on August 19, 2013.

Wohl & Fruchter’s investigation concerns whether GTX management improperly concealed from investors, among other things, that past clinical studies were deeply flawed, and thus the latest phase III trials were likely to fail.

Persons with relevant information, and GTXI shareholders with questions about this investigation, are invited to contact the attorney below, or our Firm by calling 866.833.6245.

Additional information is available on our website at: http://www.wohlfruchter.com/cases/gtxi.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

Contact:J. Elazar Fruchter ( jfruchter@wohlfruchter.com)845.425.4658 or Toll Free 866.833.6245Wohl & Fruchter LLP570 Lexington AvenueNew York, NY 10022 www.wohlfruchter.com

This release may be deemed to constitute attorney advertising.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs